Toward antibody-directed 'abzyme' prodrug therapy, ADAPT: Carbamate prodrug activation by a catalytic antibody and its in vitro application to human tumor cell killing

Paul Wentworth; Anita Datta; David Blakey

首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >Toward antibody-directed 'abzyme' prodrug therapy, ADAPT: Carbamate prodrug activation by a catalytic antibody and its in vitro application to human tumor cell killing

【24h】

Toward antibody-directed 'abzyme' prodrug therapy, ADAPT: Carbamate prodrug activation by a catalytic antibody and its in vitro application to human tumor cell killing

机译：面向抗体指导的“抗体”前药疗法，ADAPT：氨基甲酸酯前药通过催化抗体的活化及其在体外杀死人肿瘤细胞的应用

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Antibody-directed enzyme prodrug therapy, ADEPT, is a recent approach to targeted cancer chemotherapy intended to diminish the nonspecific toxicity associated with many commonly used chemotherapeutic agents. Most ADEPT systems incorporate a bacterial enzyme, and thus their po- tential is reduced because of the immunogenicity of that component of the conjugate. This limitation can be circum- vented by the use of a catalytic antibody, which can be "humanized," in place of the bacterial enzyme catalyst.

机译：抗体导向的酶前药疗法ADEPT是一种针对性靶向癌症化学疗法的最新方法，旨在减少与许多常用化学治疗剂相关的非特异性毒性。大多数ADEPT系统都结合了细菌酶，因此由于结合物成分的免疫原性，其潜力会降低。可以通过使用可以被“人源化”的催化抗体代替细菌酶催化剂来规避这一限制。

著录项

来源
《Proceedings of the National Academy of Sciences of the United States of America》 |1996年第2期|p.799-803|共5页
作者
Paul Wentworth; Anita Datta; David Blakey;
展开▼
作者单位

展开▼
收录信息美国《科学引文索引》(SCI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
原文格式 PDF
正文语种 eng
中图分类自然科学总论;
关键词

相似文献

外文文献
中文文献
专利

1. Selective chemotherapeutic strategies using catalytic antibodies: a common pro-moiety for antibody-directed abzyme prodrug therapy. [J] . Kakinuma H, Fujii I, Nishi Y Journal of Immunological Methods . 2002,第1a2期

机译：使用催化抗体的选择性化学治疗策略：抗体指导的抗体酶前药治疗的常见部分。
2. A N-NITROSOCHLOROETHYL-CEPHALOSPORIN CARBAMATE PRODRUG FOR ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY (ADEPT) [J] . Alexander RP., Pratt AJ., Kraunsoe JAE., Tetrahedron . 1996,第16期

机译：用于抗体导向的酶促药物治疗（补充）的N-硝基氯乙基-头孢菌素氨基甲酸酯产品
3. The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapies. [J] . Denny WA, Wilson WR Journal of Pharmacy and Pharmacology . 1998,第4期

机译：选择性激活的抗癌前药用作抗体导向和基因定向酶 - 前药疗法的设计。
4. Drugs to Enhance the Therapeutic Potency of Anticancer Antibodies: Antibody-Drug Conjugates as Tumor-Activated Prodrugs [C] . Walter A. Blattler, Ravi V. J. Chari American Chemical Society . 2001

机译：药物以增强抗癌抗体治疗效力：抗体 - 药物缀合物作为肿瘤活化前药
5. Murine Lymphokine-activated Killer(LAK)Cells: Establishment of LAK Cell Clones,Analysis of Target Cell Killing Mechanism and Application for Tumor Therapy [D] . 加藤和則 1991

机译：小鼠淋巴因子激活的杀伤（LAK）细胞：LAK细胞克隆的建立，靶细胞杀伤机制的分析及其在肿瘤治疗中的应用
6. Toward antibody-directed abzyme prodrug therapy ADAPT: carbamate prodrug activation by a catalytic antibody and its in vitro application to human tumor cell killing. [O] . P Wentworth, A Datta, D Blakey, 1996

机译：面向抗体导向的抗体前药疗法ADAPT：氨基甲酸酯前药通过催化抗体的活化及其在体外对人肿瘤细胞的杀伤作用。
7. Toward antibody-directed "abzyme" prodrug therapy, ADAPT: carbamate prodrug activation by a catalytic antibody and its in vitro application to human tumor cell killing. [O] . Wentworth, P, Datta, A, Blakey, D, 1996

机译：面向抗体导向的“抗体”前药疗法，ADAPT：氨基甲酸酯前药通过催化抗体的活化及其在体外对人肿瘤细胞的杀伤作用。

Toward antibody-directed 'abzyme' prodrug therapy, ADAPT: Carbamate prodrug activation by a catalytic antibody and its in vitro application to human tumor cell killing

摘要

著录项

相似文献

相关主题

期刊订阅